Nasdaq · Pharmaceutical Preparations
40 entities across 9 jurisdictions, 1 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-24 — see the exhibit.
| Entity | Jurisdiction | Note |
|---|---|---|
| BB Square Capital Investors I, LP | Delaware | |
| BB Square Capital, LLC | Delaware | |
| BB Square Holdings, LLC | Delaware | |
| BB Square Investors GP I, LLC | Delaware | |
| BB Square LP Investment, LLC | Delaware | |
| BridgeBio Chemistry, Inc. | Delaware | |
| BridgeBio Gene Therapy LLC | Delaware | |
| BridgeBio Gene Therapy Research, Inc. | Delaware | |
| BridgeBio Pharma LLC | Delaware | |
| BridgeBio Services Inc. | Delaware | |
| Calcilytix Therapeutics, Inc. | Delaware | |
| Cyan Therapeutics, Inc. | Delaware | |
| DTD Therapeutics, Inc. | Delaware | |
| Eidos Therapeutics, Inc. | Delaware | |
| CoA Therapeutics, Inc. | Delaware | |
| Origin Biosciences, Inc. | Delaware | |
| Adrenas Therapeutics, Inc. | Delaware | |
| QED Therapeutics, Inc. | Delaware | |
| Sub22, Inc. | Delaware | |
| Ferro Therapeutics, Inc. | Delaware | |
| Eulamin Therapeutics, Inc. | Delaware | |
| Cantero Therapeutics, Inc. | Delaware | |
| Venthera, Inc. | Delaware | |
| G Protein Therapeutics, Inc. | Delaware | |
| Molecular Skin Therapeutics, Inc. | Delaware | |
| Phoenix Tissue Repair, Inc. | Delaware | |
| Navire Pharma, Inc. | Delaware | |
| ML Bio Solutions, Inc. | Delaware | |
| Sen Therapeutics, Inc. | Delaware | |
| Audition Therapeutics, Inc. | Delaware | |
| BridgeBio Pharma Canada, ULC | Canada | |
| BridgeBio Pharma Cayman | Cayman Islands | offshore centre |
| BridgeBio France SAS | France | |
| BridgeBio Germany GmbH | Germany | |
| BridgeBio Pharma (HK) Limited | Hong Kong | |
| BridgeBio Europe B.V. | Netherlands | |
| BridgeBio International GmbH | Switzerland | |
| BridgeBio UK Limited | United Kingdom | |
| Evanesco Therapeutics, Inc. | Delaware | |
| BridgeBio Pharma Europe B.V. | Netherlands |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
Bankruptcy-risk screen combining working capital, retained earnings, operating income, market value against liabilities, and asset turnover. Above 2.99 is the safe zone; below 1.81 is distress.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $8.2M | −$505.5M | −$407.2M | — | 117,995,457 |
| FY2021 | $69.7M | −$586.5M | −$511.2M | — | 144,356,619 |
| FY2022 | $77.6M | −$484.7M | −$424.3M | — | 147,473,076 |
| FY2023 | $9.3M | −$653.3M | −$529.0M | — | 162,791,511 |
| FY2024 | $221.9M | −$543.3M | −$521.7M | — | 186,075,873 |
| FY2025 | $502.1M | −$732.9M | −$447.0M | — | 191,527,482 |
12 institutions tracked — 5 added, 6 reduced, 1 opened a new position.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | Active fund | 5,308,924 | +2,824,971 | $395.4M |
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 1,726,383 | −2,075,272 | $128.6M |
| BlackRock Finance, Inc. | Index | 12,448,272 | +1,981,337 | $315.3M |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 3,418,419 | −1,499,611 | $254.7M |
| JPMORGAN CHASE & CO | Active fund | 2,397,995 | +1,081,336 | $173.2M |
| CITADEL ADVISORS LLC | Hedge fund | 4,326,928 | +936,688 | $322.3M |
| STATE STREET CORP | Index | 4,435,932 | −498,388 | $330.4M |
| FMR LLC | Active fund | 2,061,307 | −282,447 | $153.5M |
| MORGAN STANLEY | Active fund | 1,693,652 | −183,707 | $126.1M |
| BANK OF AMERICA CORP /DE/ | Active fund | 1,235,380 | −50,368 | $92.0M |
| VANGUARD GROUP INC | Index | 16,862,691 | +30,632 | $1.3B |
NORGES BANK holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register. These filings span 2024-Q2–2026-Q2 rather than a single quarter, because filers report on their own schedules.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
BridgeBio Pharma, Inc. files under SIC 2834 — all 50 pharmaceutical preparations companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
